160 related articles for article (PubMed ID: 12800342)
21. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Park JW; Kang SH; Do JY
Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
[TBL] [Abstract][Full Text] [Related]
22. Ecology of the peritoneum: a substantial role for the osmotic agents resulting in apoptosis of mesothelial cells.
Gotloib L; Wajsbrot V; Shostak A
Contrib Nephrol; 2003; (140):10-7. PubMed ID: 12800339
[No Abstract] [Full Text] [Related]
23. "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.
le Poole CY; van Ittersum FJ; Valentijn RM; Teerlink T; Lindholm B; Ter Wee PM; Schalkwijk CG
Perit Dial Int; 2012; 32(1):45-54. PubMed ID: 21632443
[TBL] [Abstract][Full Text] [Related]
24. Glucose degradation products: relationship with cell damage.
Witowski J; Jörres A
Perit Dial Int; 2000; 20 Suppl 2():S31-6. PubMed ID: 10911640
[No Abstract] [Full Text] [Related]
25. PD: a biological membrane and a non-biological fluid.
Jörres A
Contrib Nephrol; 2003; (140):1-9. PubMed ID: 12800338
[No Abstract] [Full Text] [Related]
26. 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma.
Erixon M; Wieslander A; Lindén T; Carlsson O; Jönsson JA; Simonsen O; Kjellstrand P
Perit Dial Int; 2009 Feb; 29 Suppl 2():S28-31. PubMed ID: 19270226
[TBL] [Abstract][Full Text] [Related]
27. Initial experience with icodextrin in Indian patients.
Bhowmik D; Khaira A; Mahajan S; Tiwari SC
Perit Dial Int; 2007; 27(4):467-8. PubMed ID: 17602160
[No Abstract] [Full Text] [Related]
28. Continuous flow peritoneal dialysis: current perspectives.
Amerling R; Glezerman I; Savransky E; Dubrow A; Ronco C
Contrib Nephrol; 2003; (140):294-304. PubMed ID: 12800371
[No Abstract] [Full Text] [Related]
29. Strategies to reduce glucose exposure in peritoneal dialysis patients.
Holmes CJ; Shockley TR
Perit Dial Int; 2000; 20 Suppl 2():S37-41. PubMed ID: 10911641
[TBL] [Abstract][Full Text] [Related]
30. Comparison between standard single chamber versus dual chamber low glucose degradation product peritoneal dialysis fluids.
Vareesangthip K; Vongsanim S; Fan S; Davenport A
Artif Organs; 2021 Jan; 45(1):88-94. PubMed ID: 32645750
[TBL] [Abstract][Full Text] [Related]
31. Impact of glucose in peritoneal dialysis: saint or sinner?
Sitter T; Sauter M
Perit Dial Int; 2005; 25(5):415-25. PubMed ID: 16178471
[TBL] [Abstract][Full Text] [Related]
32. What is the role of automated peritoneal dialysis and continuous flow peritoneal dialysis?
Diaz-Buxo JA
Contrib Nephrol; 2003; (140):264-71. PubMed ID: 12800368
[No Abstract] [Full Text] [Related]
33. Alterations of dialysate markers in chronic peritoneal dialysis patients treated with the new less bioincompatible bicarbonate solutions.
Theodoridis M; Thodis E; Tsigalou C; Pappi R; Roumeliotis A; Georgoulidou A; Passadakis P; Vargemezis V
Perit Dial Int; 2011; 31(2):196-9. PubMed ID: 21427248
[No Abstract] [Full Text] [Related]
34. Chylous Peritoneal Dialysate Related to the Use of Nutritional Supplements in a Patient with Clostridium difficile Diarrhea.
Tok PL; Wong YT; Thangaraju S; Foo WY
Perit Dial Int; 2017 Jan; 37(1):124-125. PubMed ID: 28153974
[No Abstract] [Full Text] [Related]
35. Effects of glucose-free dialysis solutions on human peritoneal mesothelial cells.
Chang JM; Lin SP; Lai YH; Chen HC
Am J Nephrol; 2007; 27(2):206-11. PubMed ID: 17377374
[TBL] [Abstract][Full Text] [Related]
36. Status epilepticus and hyperprolinaemia following recurrent gelatine administrations in a patient on peritoneal dialysis.
Illsinger S; Lücke T; Offner G; Hartmann H; Das AM
Nephrol Dial Transplant; 2006 May; 21(5):1417-9. PubMed ID: 16396972
[No Abstract] [Full Text] [Related]
37. Ten years after MIDAS: icodextrin lights and shadows.
Amici G; Da Rin G; Agostini A; Velo S; Bocci C
Contrib Nephrol; 2003; (140):76-81. PubMed ID: 12800346
[No Abstract] [Full Text] [Related]
38. Long-term peritoneal dialysis-impact of peritoneal membrane changes and newer solutions.
Krediet RT
Int J Artif Organs; 1998 Aug; 21(8):437-9. PubMed ID: 9803343
[No Abstract] [Full Text] [Related]
39. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo.
Zareie M; Hekking LH; Welten AG; Driesprong BA; Schadee-Eestermans IL; Faict D; Leyssens A; Schalkwijk CG; Beelen RH; ter Wee PM; van den Born J
Nephrol Dial Transplant; 2003 Dec; 18(12):2629-37. PubMed ID: 14605288
[TBL] [Abstract][Full Text] [Related]
40. Personal dialysis capacity (PDC(TM)) test: a multicentre clinical study.
Van Biesen W; Carlsson O; Bergia R; Brauner M; Christensson A; Genestier S; Haag-Weber M; Heaf J; Joffe P; Johansson AC; Morel B; Prischl F; Verbeelen D; Vychytil A
Nephrol Dial Transplant; 2003 Apr; 18(4):788-96. PubMed ID: 12637650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
